Tauriga Sciences Inc. Confirms That It's on Pace for a Strong Quarter From Its Retail Business
Tauriga Sciences, Inc. (TAUG) confirmed strong momentum in its 2nd Fiscal Quarter 2022, reporting July 2021 net revenues exceeding $60,000. The company is seeing increased demand for its Tauri-Gum™ product line, including the newly launched Delta 8 THC chewing gum. Enhanced manufacturing processes have resulted in cost savings without compromising quality. Tauriga is focused on expanding its customer base and revenue growth, with ongoing initiatives in the CBD and CBG edibles market, alongside its pharmaceutical development efforts targeting nausea regulation for chemotherapy patients.
- Net revenue for July 2021 exceeded $60,000.
- Strong demand for Tauri-Gum™ product line and new Delta 8 THC gum.
- Successful integration of cost-saving measures in manufacturing.
- None.
The Company’s Current Operating Quarter is Its 2nd Fiscal Quarter 2022 (Period: July 1, 2021 – September 30, 2021)
NEW YORK, NY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, has today confirmed that it’s on pace for a strong Quarter from its retail business. The Company’s current operating Quarter is its 2nd Fiscal Quarter 2022 (Period: July 1, 2021 – September 30, 2021). During the month of July 2021, the Company has experienced acceleration in both demand and interest, for its enhanced products and product lines as well as its innovative, newly introduced, product offerings. The Company has also been successful in integrating cost saving measures into its manufacturing processes, without even the slightest compromise of quality.
For Month of July 2021: Net Revenue Exceeded
The Company’s enhanced Tauri-Gum™ product line (its flagship brand) has been well received by both existing E-Commerce customers as well as prospective retail customers (of all sizes). The Company is confident in the competitiveness of its established wholesale pricing, which preserve solid “built in” gross margins for its future anticipated revenue growth.
Additionally - The Company is excited about the commercial launch of its innovative, Delta 8 THC (10mg) infused chewing gum; Evergreen Mint Flavor version of Tauri-Gum™.
With inventory now available for all of its products and enhanced product lines, the Company will be focused on meaningfully growing its revenue and continually acquiring new customers. There are many exciting corporate initiatives that are currently underway and the Company looks forward to updating its shareholders as material progress is realized.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
FAQ
What were Tauriga Sciences' revenues in July 2021?
What new products did Tauriga Sciences launch?
What is Tauriga Sciences' primary product line?
What fiscal quarter is Tauriga Sciences currently in?
How is Tauriga Sciences managing its manufacturing costs?
